Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR2 | O95665 | 8/20 | 0.99 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.69 |
| ▸ | APLNR | P35414 | 6/20 | 0.55 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.47 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24473647 | 1.00 | NTSR2 (0.99) | NTSR2NTSR1APLNRSSTR2SSTR5 | |
| SCHEMBL24473552 | 1.00 | NTSR2 (0.99) | NTSR2NTSR1APLNRSSTR2SSTR5 | |
| SCHEMBL24473377 | 0.99 | NTSR2 (1.00) | NTSR2NTSR1APLNRSSTR2SSTR5 | |
| SCHEMBL24473463 | 0.99 | NTSR2 (1.00) | NTSR2NTSR1APLNRSSTR2SSTR5 | |
| SCHEMBL24473299 | 0.99 | NTSR2 (1.00) | NTSR2NTSR1APLNRSSTR2SSTR5 | |
| SCHEMBL24473381 | 0.99 | NTSR2 (1.00) | NTSR2NTSR1APLNRSSTR2SSTR5 | |
| SCHEMBL24473592 | 0.99 | NTSR2 (1.00) | NTSR2NTSR1APLNRSSTR2SSTR5 | |
| SCHEMBL24473428 | 0.99 | NTSR2 (1.00) | NTSR2NTSR1APLNRSSTR2SSTR5 | |
| SCHEMBL24473476 | 0.99 | NTSR2 (1.00) | NTSR2NTSR1APLNRSSTR2SSTR5 | |
| SCHEMBL24473420 | 0.99 | NTSR2 (1.00) | NTSR2NTSR1APLNRSSTR2SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | NTSR2 2/4885NTSR1 5/4885APLNR 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.